ELTX
Elicio Therapeutics, Inc.
Key Financials
Net Income
$-39571000
↑ 23.8%
Revenue
$2.3M
↓ 91.9%
Operating Income
$-37714000
↑ 16.2%
EPS (Diluted)
$-2.58
↑ 39.3%
Total Assets
$25.9M
↓ 8.2%
Shareholders' Equity
$1.6M
↑ 114.5%
Cash & Equivalents
$18.6M
↑ 5.4%
Total Liabilities
$24.2M
↓ 38.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/14/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ELTX |
| Company Name | Elicio Therapeutics, Inc. |
| CIK | 1601485 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (857) 209-0050 |